Skip to main content
Premium Trial:

Request an Annual Quote

Thomson Reuters Provides Access to Life Science Data through Accelrys Software

NEW YORK (GenomeWeb News) — Accelrys will provide its customers access to life sciences content available from Thomson Reuters' Cortellis for Informatics via its Enterprise Platform and related Accelrys software offerings including Pipeline Pilot, Symyx Notebook by Accelrys, and Isentris, the San Diego-based informatics firm said today.

The Accelrys Enterprise Platform provides a service-oriented architecture that enables the integration and deployment of scientific solutions across multiple domains in the lab-to-plant process. Cortellis for Informatics provides web services for investigational drugs, drug targets, ontologies, patents, clinical trials, and analytics in biopharmaceutical research and development. The platform was launched earlier this year.

Matt Hahn, Accelrys' senior vice president and chief technology officer, said in a statement that the agreement provides life scientists with "convenient access to expertly refined content and analysis tools through a single, user-friendly source."

Joseph Donahue, Thomson Reuters' senior vice president, added that the partnership should "offer more options to our mutual customers to access, analyze, and drive actionable decisions from key content."

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.